Susquehanna Fundamental Investments, LLC Aldeyra Therapeutics, Inc. Transaction History

Susquehanna Fundamental Investments, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$3.5 - $9.63 $96,358 - $265,123	-27,531 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$7.94 - $11.31 $65,822 - $93,759	-8,290 Reduced 23.14%	27,531 $242,000
Q2 2021 Aug 11, 2021	SELL	$10.44 - $14.85 $373,856 - $531,778	-35,810 Reduced 49.99%	35,821 $406,000
Q1 2021 May 17, 2021	BUY	$6.53 - $14.42 $2,677 - $5,912	410 Added 0.58%	71,631 $851,000
Q4 2020 Feb 16, 2021	BUY	$6.31 - $8.13 $109,926 - $141,632	17,421 Added 32.38%	71,221 $489,000
Q3 2020 Nov 16, 2020	BUY	$4.0 - $7.53 $18,400 - $34,638	4,600 Added 9.35%	53,800 $399,000
Q2 2020 Aug 14, 2020	BUY	$1.97 - $5.05 $96,924 - $248,460	49,200 New	49,200 $205,000

106

35.1M

153K

83.9K

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $311M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

Get notified when there are updates to the investment portfolio of Susquehanna Fundamental Investments, LLC, based on Form 13F filings with the SEC.

Stay updated on Susquehanna Fundamental Investments, LLC with notifications on news.